(0.09%) 5 159.25 points
(0.08%) 38 862 points
(0.02%) 18 005 points
(0.90%) $78.81
(-0.28%) $2.14
(0.94%) $2 330.30
(2.52%) $27.36
(0.47%) $969.80
(0.01%) $0.929
(-0.22%) $10.85
(-0.16%) $0.796
(0.11%) $91.55
Live Chart Being Loaded With Signals
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe...
Stats | |
---|---|
Dzisiejszy wolumen | 0 |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 0 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Dynavax Technologies Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dynavax Technologies Finanse
Annual | 2020 |
Przychody: | $46.55M |
Zysk brutto: | $32.64M (70.12 %) |
EPS: | $-0.750 |
FY | 2020 |
Przychody: | $46.55M |
Zysk brutto: | $32.64M (70.12 %) |
EPS: | $-0.750 |
FY | 2019 |
Przychody: | $35.22M |
Zysk brutto: | $15.83M (44.95 %) |
EPS: | $0 |
FY | 2018 |
Przychody: | $8.20M |
Zysk brutto: | $-13.60M (-165.87 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej